European Journal of Cancer
Volume 45, Issue 1 , Pages 99-106 , January 2009

Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with wilms tumour

  • Najat C. Daw

      Affiliations

    • Department of Oncology, Mail Stop 260, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, TN 38105-3678, USA
    • Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    • Corresponding Author InformationCorresponding author: Address: Department of Oncology, Mail Stop 260, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, TN 38105-3678, USA. Tel.: +1 901 595 2573; fax: +1 901 521 9005.
    • ,
  • David Gregornik

      Affiliations

    • Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
    • ,
  • John Rodman

      Affiliations

    • Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
    • Deceased.
    • ,
  • Neyssa Marina

      Affiliations

    • Department of Oncology, Mail Stop 260, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, TN 38105-3678, USA
    • Present address: Pediatric Hematology/Oncology, Stanford University Medical Center, Palo Alto, California, USA.
    • ,
  • Jianrong Wu

      Affiliations

    • Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
    • ,
  • Larry E. Kun

      Affiliations

    • Department of Radiological Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
    • ,
  • Jesse J. Jenkins

      Affiliations

    • Department of Pathology and Laboratory Medicine, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
    • ,
  • Valerie McPherson

      Affiliations

    • Department of Oncology, Mail Stop 260, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, TN 38105-3678, USA
    • ,
  • Judith Wilimas

      Affiliations

    • Department of Oncology, Mail Stop 260, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, Tennessee, TN 38105-3678, USA
    • ,
  • Deborah P. Jones

      Affiliations

    • Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    • Children’s Foundation Research Center at LeBonheur Children’s Medical Center, Memphis, Tennessee, USA

Received 4 July 2008 ,Revised 26 August 2008 ,Accepted 25 September 2008.

References 

  1. Green DM. The treatment of stages I–IV favorable histology Wilms’ tumor. J Clin Oncol. 2004;22(8):1366–1372
  2. Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms’ tumor: results from the fifth National Wilms’ Tumor Study. J Clin Oncol. 2006;24(15):2352–2358
  3. Tournade MF, Com-Nougue C, de Kraker J, et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms’ tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms’ Tumor Trial and Study. J Clin Oncol. 2001;19(2):488–500
  4. Ritchey ML, Kelalis PP, Haase GM, Shochat SJ, Green DM, D’Angio G. Preoperative therapy for intracaval and atrial extension of Wilms tumor. Cancer. 1993;71(12):4104–4110
  5. Ritchey ML, Pringle KC, Breslow NE, et al. Management and outcome of inoperable Wilms tumor. A report of National Wilms Tumor Study-3. Ann Surg. 1994;220(5):683–690
  6. Lemerle J, Voute PA, Tournade MF, et al. Effectiveness of preoperative chemotherapy in Wilms’ tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol. 1983;1(10):604–609
  7. Tournade MF, Com-Nougue C, Voute PA, et al. Results of the Sixth International Society of Pediatric Oncology Wilms’ Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms’ tumor. J Clin Oncol. 1993;11(6):1014–1023
  8. Bonadio JF, Storer B, Norkool P, Farewell VT, Beckwith JB, D’Angio GJ. Anaplastic Wilms’ tumor: clinical and pathologic studies. J Clin Oncol. 1985;3(4):513–520
  9. D’Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms’ tumor. Results of the Third National Wilms’ Tumor Study. Cancer. 1989;64(2):349–360
  10. Green DM, Beckwith JB, Breslow NE, et al. Treatment of children with stages II to IV anaplastic Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol. 1994;12(10):2126–2131
  11. Tournade MF, Lemerle J, Brunat-Mentigny M, et al. Ifosfamide is an active drug in Wilms’ tumor: a phase II study conducted by the French Society of Pediatric Oncology. J Clin Oncol. 1988;6(5):793–796
  12. Pein F, Pinkerton R, Tournade MF, et al. Etoposide in relapsed or refractory Wilms’ tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children’s Cancer Study Group. J Clin Oncol. 1993;11(8):1478–1481
  13. de Camargo B, Melaragno R, Saba e Silva, et al. Phase II study of carboplatin as a single drug for relapsed Wilms’ tumor: experience of the Brazilian Wilms’ Tumor Study Group. Med Pediatr Oncol. 1994;22(4):258–260
  14. Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Children’s Cancer Group. Cancer. 1994;73(4):1297–1301
  15. Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children’s cancer group report. J Pediatr Hematol Oncol. 2001;23(1):30–38
  16. Tannous R, Giller R, Holmes E, et al. Intensive therapy for high risk (HR) relapsed Wilms’ tumor (WT). A Ccg-4921/Pog-9445 Study Report, 19 ed. 2000; p. 588a.
  17. Kung FH, Desai SJ, Dickerman JD, et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol. 1995;17(3):265–269
  18. Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Oncol Rep. 2008;50(2):236–241
  19. Marina NM, Wilimas JA, Meyer WH, Jones DP, Douglass EC, Pratt CB. Refining therapeutic strategies for patients with resistant Wilm’s tumor. Am J Pediatr Hematol Oncol. 1994;16(4):296–300
  20. Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms’ tumor: a Children’s Cancer Group report. Ann Oncol. 2002;13(3):460–469
  21. Hayslett JP. Effect of age on compensatory renal growth. Kidney Int. 1983;23(4):599–602
  22. Potter DE, Leumann EP, Sakai T, Holliday MA. Early responses of glomerular filtration rate to unilateral nephrectomy. Kidney Int. 1974;5(2):131–136
  23. Wikstad I, Pettersson BA, Elinder G, Sokucu S, Aperia A. A comparative study of size and function of the remnant kidney in patients nephrectomized in childhood for Wilms’ tumor and hydronephrosis. Acta Paediatr Scand. 1986;75(3):408–414
  24. Green DM, Coppes MJ, Breslow NE, et al. Wilms tumor. In:  Pizzo PA,  Poplack DG editor. Principles and practice of pediatric oncology. third ed.. Philadelphia: Lippincott – Raven; 1997;p. 733–759
  25. Rodman JH, Maneval DC, Magill HL, Sunderland M. Measurement of Tc-99m DTPA serum clearance for estimating glomerular filtration rate in children with cancer. Pharmacotherapy. 1993;13(1):10–16
  26. Marina NM, Rodman J, Shema SJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol. 1993;11(3):554–560
  27. Marina NM, Rodman JH, Murry DJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. J Natl Cancer Inst. 1994;86(7):544–548
  28. Murry DJ, Synold TW, Pui CH, Rodman JH. Renal function and methotrexate clearance in children with newly diagnosed leukemia. Pharmacotherapy. 1995;15(2):144–149
  29. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58(2):259–263
  30. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254
  31. Alon U, Hellerstein S. Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr Nephrol. 1994;8(2):250–251
  32. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8(2):135–160
  33. Matos V, van Melle G, Boulat O, Markert M, Bachmann C, Guignard JP. Urinary phosphate/creatinine, calcium/creatinine, and magnesium/creatinine ratios in a healthy pediatric population. J Pediatr. 1997;131(2):252–257
  34. Stark H, Eisenstein B, Tieder M, Rachmel A, Alpert G. Direct measurement of TP/GFR: a simple and reliable parameter of renal phosphate handling. Nephron. 1986;44(2):125–128
  35. Schell M, Cochat P, Hadj-Aissa A, Bouffet E, Dubourg L, Brunat-Mentigny M. Renal function following unilateral nephrectomy for neuroblastoma and Wilms’ tumour. Pediatr Nephrol. 1995;9(5):579–582
  36. de Graaf SS, van Gent H, Reitsma-Bierens WC, van Luyk WH, Dolsma WV, Postma A. Renal function after unilateral nephrectomy for Wilms’ tumour: the influence of radiation therapy. Eur J Cancer. 1996;32A(3):465–469
  37. Levitt GA, Yeomans E, Dicks MC, Breatnach F, Kingston J, Pritchard J. Renal size and function after cure of Wilms’ tumour. Br J Cancer. 1992;66(5):877–882
  38. Jones DP, Chesney RW. Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin. Curr Opin Pediatr. 1995;7(2):208–213
  39. Rossi R, Godde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol. 1994;12(1):159–165
  40. Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol. 1993;11(1):173–190
  41. Ashraf MS, Brady J, Breatnach F, Deasy PF, O’Meara A. Ifosfamide nephrotoxicity in paediatric cancer patients. Eur J Pediatr. 1994;153(2):90–94
  42. Schwartz GJ. Clinical assessment of renal function. In:  Kher KK,  Schnapper HW,  Makker SP editor. Clinical pediatric nephrology. 2nd ed.. Boca Raton, FL: Taylor and Francis; 2007;p. 71–93

PII: S0959-8049(08)00749-1

doi: 10.1016/j.ejca.2008.09.017

European Journal of Cancer
Volume 45, Issue 1 , Pages 99-106 , January 2009

Article Tools

* Image Usage & Resolution